TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Transitional Care Program Involving an Advanced Practice Nurse on 30-Day Hospital Readmissions for Elderly Patients Discharged From a Short Stay Geriatric Ward (PROUST Study)
Brief Summary: In France, it has be estimated that the hospital readmission rate within 30 days of patients aged 75 or older is 14% (IC95% \[12.0-16.7\]), nearly a quarter being avoidable. There is evidence that interventions "bridging" the transition from hospital to home involving a dedicated professional (usually nurses) would be most effective in reducing the risk of readmission, but the level of evidence of current studies is low. Our study aims to assess the impact of a program of transitional care from hospital to home for people of 75 years old or more admitted to acute care.


Options:
A: Arm Label: TCM integrated group; Type: ACTIVE_COMPARATOR; Interventions: Other: acupuncture, massage and basic TCM treatment | Arm Label: Western Medicine group; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation and WM basic treatment | Intervention Type: OTHER; Name: acupuncture, massage and basic TCM treatment; Assigned to Arm(s): TCM integrated group | Intervention Type: OTHER; Name: rehabilitation and WM basic treatment; Assigned to Arm(s): Western Medicine group
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: reconciliation | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: reconciliation; Assigned to Arm(s): intervention
C: Arm Label: Transitional care program.; Type: EXPERIMENTAL; Interventions: Other: Transitional care program. | Arm Label: standard care program; Type: OTHER; Interventions: Other: standard care program | Intervention Type: OTHER; Name: Transitional care program.; Assigned to Arm(s): Transitional care program. | Intervention Type: OTHER; Name: standard care program; Assigned to Arm(s): standard care program
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)
Brief Summary: Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).


Options:
A: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurbinectedin (PM01183) | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated liposomal doxorubicin (PLD), Drug: Topotecan | Intervention Type: DRUG; Name: Lurbinectedin (PM01183); Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Arm B
C: Arm Label: CAELYX; Type: EXPERIMENTAL; Interventions: Drug: CAELYX | Arm Label: Topotecan hydrochloride (HCl); Type: ACTIVE_COMPARATOR; Interventions: Drug: Topotecan HCl | Intervention Type: DRUG; Name: CAELYX; Assigned to Arm(s): CAELYX | Intervention Type: DRUG; Name: Topotecan HCl; Assigned to Arm(s): Topotecan hydrochloride (HCl)
D: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Males, Antioxidants, and Infertility (MOXI) Trial
Brief Summary: The objective of the Males, Antioxidants, and Infertility (MOXI) Trial is to examine whether treatment of infertile males with an antioxidant formulation improves male fertility. The central hypothesis is that treatment of infertile males with antioxidants will improve sperm structure and function, resulting in higher fertilization rates and improved embryo development, leading to higher pregnancy and live birth rates. Findings from this research will be significant in that they will likely lead to an effective, non-hormonal treatment modality for male infertility. An effective treatment for men would also reduce the treatment burden on the female partner, lower costs, and provide effective alternatives to couples with religious or ethical contraindications to ART (Assisted Reproductive Technology). If antioxidants do not improve pregnancy rates, but do improve sperm motility and DNA integrity, they could allow for couples with male factor infertility to use less intensive therapies such as intrauterine insemination. Male fertility specialists currently prescribe antioxidants based on the limited data supporting their use. A negative finding, lack of any benefit, would also alter current treatment of infertile males.


Options:
A: Arm Label: Folic acid and zinc supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 5 mg folic acid and 30 mg elemental zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 5 mg folic acid and 30 mg elemental zinc; Assigned to Arm(s): Folic acid and zinc supplementation | Intervention Type: DRUG; Name: Placebo Comparator: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Antioxidant; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Androferti | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Androferti; Assigned to Arm(s): Antioxidant | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cholecalciferol + calcium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol and calcium | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Cholecalciferol and calcium; Assigned to Arm(s): Cholecalciferol + calcium | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Antioxidant Supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antioxidant Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Antioxidant Supplement; Assigned to Arm(s): Antioxidant Supplement | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of S(+)-Ketamine Administered as a Continuous Infusion for the Control of Postoperative Pain: a Randomized Controlled Trial
Brief Summary: Background: The use of low-dose continuous infusion of S(+)-ketamine combined with target-controlled intravenous anesthesia with remifentanil and propofol may be related to the control of postoperative pain and of opioid-induced hyperalgesia. The present study aimed to evaluate the efficacy of continuous infusion of S(+)-ketamine given intraoperatively in the control of postoperative pain compared to placebo.


Options:
A: Arm Label: morphine only; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: morphine ketamine; Type: EXPERIMENTAL; Interventions: Drug: morphine ketamine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine only | Intervention Type: DRUG; Name: morphine ketamine; Assigned to Arm(s): morphine ketamine
B: Arm Label: C group; Type: PLACEBO_COMPARATOR; Interventions: Drug: NS infusion | Arm Label: KET group; Type: EXPERIMENTAL; Interventions: Drug: Ketamine infusion | Intervention Type: DRUG; Name: Ketamine infusion; Assigned to Arm(s): KET group | Intervention Type: DRUG; Name: NS infusion; Assigned to Arm(s): C group
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ketamine | Intervention Type: DRUG; Name: ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: S(+)-ketamine group (SG); Type: ACTIVE_COMPARATOR; Interventions: Drug: S(+)-Ketamine | Arm Label: placebo group (PG); Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: S(+)-Ketamine; Assigned to Arm(s): S(+)-ketamine group (SG)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telephone-Delivered Interventions for Smoking Cessation
Brief Summary: The purpose of this study is to demonstrate that Acceptance and Commitment Therapy's (ACT) implementation outcomes are at least as good as those of traditional cognitive behavioral therapy (CBT).


Options:
A: Arm Label: Mindfulness-Based Treatment Group (MBAT); Type: EXPERIMENTAL; Interventions: Behavioral: MBAT Group Therapy, Drug: Nicotine | Arm Label: Standard Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Group Therapy | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Individual Therapy | Intervention Type: BEHAVIORAL; Name: MBAT Group Therapy; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT) | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT), Standard Care Group, Usual Care Group | Intervention Type: BEHAVIORAL; Name: Group Therapy; Assigned to Arm(s): Standard Care Group | Intervention Type: BEHAVIORAL; Name: Individual Therapy; Assigned to Arm(s): Usual Care Group
B: Arm Label: TALK study group; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Delivered Intervention | Arm Label: TALK control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Delivered Intervention | Intervention Type: BEHAVIORAL; Name: Telephone Delivered Intervention; Assigned to Arm(s): TALK control group, TALK study group
C: Arm Label: Mindfulness Based Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness based smoking cessation | Arm Label: Behavioral Smoking Cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Smoking Cessation intervention | Intervention Type: BEHAVIORAL; Name: Mindfulness based smoking cessation; Assigned to Arm(s): Mindfulness Based Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Smoking Cessation intervention; Assigned to Arm(s): Behavioral Smoking Cessation
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness training | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness training | Intervention Type: BEHAVIORAL; Name: Mindfulness training; Assigned to Arm(s): Control group, Intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Different Montages of Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke Patients: a Randomized Controlled Trial
Brief Summary: Transcranial direct current stimulation (tDCS) has shown promising results in the modulation of cortical excitability and the promotion of neuronal plasticity after stroke. The purpose of this study was to compare the effectiveness of three different montages of tDCS (anodal, cathodal and bilateral) in reducing the risk of falls and recovery of lower limb function in acute stroke patients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Intervention Type: DEVICE; Name: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 2
B: Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: Together in Movement and Exercise (TIME) Program | Arm Label: Wait-listed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Together in Movement and Exercise (TIME) Program; Assigned to Arm(s): Experimental Group
C: Arm Label: Anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Anodal transcranial direct current stimulation | Arm Label: Cathodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Cathodal transcranial direct current stimulation | Arm Label: Bilateral tDCS; Type: EXPERIMENTAL; Interventions: Device: Bilateral transcranial direct current stimulation | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcranial direct current stimulation | Intervention Type: DEVICE; Name: Anodal transcranial direct current stimulation; Assigned to Arm(s): Anodal tDCS | Intervention Type: DEVICE; Name: Cathodal transcranial direct current stimulation; Assigned to Arm(s): Cathodal tDCS | Intervention Type: DEVICE; Name: Bilateral transcranial direct current stimulation; Assigned to Arm(s): Bilateral tDCS | Intervention Type: DEVICE; Name: Sham transcranial direct current stimulation; Assigned to Arm(s): Sham tDCS
D: Arm Label: Guided Self-rehabilitation Contract; Type: ACTIVE_COMPARATOR; Interventions: Other: Guided Self-rehabilitation Contract | Arm Label: Conventional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Guided Self-rehabilitation Contract; Assigned to Arm(s): Guided Self-rehabilitation Contract

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study
Brief Summary: The purpose of the study is to assess the efficacy and safety of paracetamol in comparison to ibuprofen in the treatment of patent ductus arteriosus (PDA) in preterm infants.


Options:
A: Arm Label: early ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Early ibuprofen | Arm Label: Late Ibuprofen expectant group (placebo); Type: OTHER; Interventions: Other: Late ibuprofen expectant group (placebo) | Intervention Type: DRUG; Name: Early ibuprofen; Assigned to Arm(s): early ibuprofen | Intervention Type: OTHER; Name: Late ibuprofen expectant group (placebo); Assigned to Arm(s): Late Ibuprofen expectant group (placebo)
B: Arm Label: Oral paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral paracetamol | Arm Label: Oral ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ibuprofen | Intervention Type: DRUG; Name: Oral paracetamol; Assigned to Arm(s): Oral paracetamol | Intervention Type: DRUG; Name: Oral ibuprofen; Assigned to Arm(s): Oral ibuprofen
C: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen
D: Arm Label: 1: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone | Arm Label: 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1: hydrocortisone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2: Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study
Brief Summary: The purpose of the study is to assess the efficacy and safety of paracetamol in comparison to ibuprofen in the treatment of patent ductus arteriosus (PDA) in preterm infants.


Options:
A: Arm Label: Paracetamol effect on ductus; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Arm Label: Paracetamol effect on pain; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain | Intervention Type: DRUG; Name: 0.45 % saline solution; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
C: Arm Label: Ibuprofen group; Type: N/A; Interventions: Drug: Ibuprofen (Sanofi, Istanbul, Turkey) | Arm Label: Paracetamol group; Type: N/A; Interventions: Drug: Paracetamol (GlaxoSmithKline, Istanbul, Turkey) | Intervention Type: DRUG; Name: Ibuprofen (Sanofi, Istanbul, Turkey); Assigned to Arm(s): Ibuprofen group | Intervention Type: DRUG; Name: Paracetamol (GlaxoSmithKline, Istanbul, Turkey); Assigned to Arm(s): Paracetamol group
D: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to study the effect of anticoagulation in immune response with Acute Kidney Injury (AKI) undergoing Continuous Renal Replacement Therapy (CRRT).


Options:
A: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
B: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming
C: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
D: Arm Label: CVVH arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the CVVH method | Arm Label: IHD arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the IHD (intermittent HD) | Intervention Type: OTHER; Name: RRT for acute kidney failure using the CVVH method; Assigned to Arm(s): CVVH arm | Intervention Type: OTHER; Name: RRT for acute kidney failure using the IHD (intermittent HD); Assigned to Arm(s): IHD arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to study the effect of anticoagulation in immune response with Acute Kidney Injury (AKI) undergoing Continuous Renal Replacement Therapy (CRRT).


Options:
A: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
B: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
C: Arm Label: RCA Group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation) | Arm Label: Heparin group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin) | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation); Assigned to Arm(s): RCA Group | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin); Assigned to Arm(s): Heparin group
D: Arm Label: heparin; Type: PLACEBO_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Arm Label: citrate regional anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): heparin | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): citrate regional anticoagulation, heparin

Answer: B